AGTR1 and COVID-19: Therefore, considering the imbalance of the RAS family (overactivation of the ACE-Ang II-AGTR1 axis) in COVID-19, a combination of ACEIs/ARBs and ICIs could be considered for use in cancer patients infected with SARS-CoV-2.